Unlike the Get Better campaign — which was built throughout last year — Seeking launched with a full body of creative work, ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

People taking Zepbound, Eli Lilly’s obesity drug, lost almost 50% more weight than individuals using Novo Nordisk’s Wegovy.

Pharmaceutical company Eli Lilly’s study of its tablet, orforglipron, has raised hopes of an effective and easy-to-use treatment reaching a market dominated by injections.

(The most famous example is Prozac.) To be clear, the word "orforglipron" won't appear on Eli Lilly's consumer-facing packaging if it ever hits the market. It's the drug's generic name, so it ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...